MarketPulse
N

$NSRX

3 articles found
3 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nasus Pharma Advances NS002 to Pivotal Stage on Positive Phase 2 Data

Nasus Pharma reports positive Phase 2 data for NS002 intranasal epinephrine, planning pivotal study Q4 2026 with strong cash position through Q2 2027.
NSRXPhase 2 clinical trialPivotal Study
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nasus Pharma CEO to Present Pipeline at Three Major Healthcare Conferences

Nasus Pharma CEO presents clinical pipeline at three major healthcare conferences in February-March, showcasing NS002 intranasal epinephrine for anaphylaxis treatment.
NSRXclinical-stageinvestor conference
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nasus Pharma Closes $15M Capital Raise to Fund Epinephrine Product Development

Nasus Pharma raises $15M to advance intranasal epinephrine product toward FDA trials. Funds support NS002 development and pipeline expansion.
NSRXprivate placementcapital raise